Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study
Taylor P, Schett G, Huizinga T, Wang Q, Ibrahim F, Zhou B, Liva S, Shaik J, Xiong Y, Leu J, Panchakshari R, Loza M, Ma K, Dhatt H, Cella R, Karyekar C, Cuff C, Gao S, Fei K. Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. RMD Open 2024, 10: e004278. PMID: 38942592, PMCID: PMC11227837, DOI: 10.1136/rmdopen-2024-004278.Peer-Reviewed Original ResearchConceptsAnticitrullinated protein antibodiesModerate to severe active rheumatoid arthritisSevere active rheumatoid arthritisPatient-reported outcomesActive rheumatoid arthritisRheumatoid arthritisPrimary endpointAntitumour necrosis factor agentsInadequate responseModerate to severe active RAReduced serum immunoglobulin GAmerican College of Rheumatology (ACR) criteriaCirculating immune complex levelsPhase 2a studySevere active RAAnti-TNF therapyImmune complex levelsSerum inflammatory markersSerious adverse eventsStatistical significanceDAS28-CRP remissionSerum immunoglobulin GEfficacy endpointClinical improvementEfficacy benefits